These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 264153)

  • 1. Diphenylhydantoin and pulmonary function.
    Smith RJ; Man GC; Man SF; McLean DR
    Can J Neurol Sci; 1979 Feb; 6(1):21-5. PubMed ID: 264153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Serum diphenylhydantoin in epileptic patients (preliminary report)].
    Radzikowska B; Zadrozyńska E; Pakszys W
    Neurol Neurochir Pol; 1977; 11(5):551-4. PubMed ID: 593505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Studies of the effect of 5,5-diphenylhydantoin on the bioelectric activity of the brain in epilepsy].
    Domzal T; Gajkowski K
    Neurol Neurochir Pol; 1971; 5(3):301-6. PubMed ID: 5000628
    [No Abstract]   [Full Text] [Related]  

  • 4. Is free fraction measurement of phenytoin always necessary in pediatric epileptic patients?
    Johno I; Kuzuya T; Suzuki K; Hasegawa M; Nakamura T; Kitazawa S; Aso K; Watanabe K
    Ther Drug Monit; 1988; 10(1):39-44. PubMed ID: 3376180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormalities in liver function tests during long-term diphenylhydantoin therapy in epileptic out-patients.
    Andreasen PB; Lyngbye J; Trolle E
    Acta Med Scand; 1973 Oct; 194(4):261-4. PubMed ID: 4749163
    [No Abstract]   [Full Text] [Related]  

  • 6. [Association of pyrithioxin and diphenylhydantoin in the treatment of organic epileptic syndromes].
    Martínez-Lage JM; Molina P; Madoz P
    Med Clin (Barc); 1965 Sep; 45(3):204-5. PubMed ID: 5861606
    [No Abstract]   [Full Text] [Related]  

  • 7. [A change in the thyroid status of children with epilepsy being treated with diphenylhydantoin].
    Temin PA; Shapoval'iants IM; Nikanorova MIu; Freĭdkova NV; Plotnikova IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 1995; 95(3):25-9. PubMed ID: 7571918
    [No Abstract]   [Full Text] [Related]  

  • 8. Interrelation at plasmatic level between antiepileptic drugs and lipids. Its implications in the efficiency of treatment in epilepsy. I. Changes induced by phenobarbital or/and diphenylhydantoin in serum lipids.
    Rogozea R; Florea-Ciocoiu V; Bălăiţă C; Luca N
    Neurol Psychiatr (Bucur); 1980; 18(2):69-77. PubMed ID: 7414244
    [No Abstract]   [Full Text] [Related]  

  • 9. Increased depressant effect of phenytoin sodium as compared to carbamazepine on cortical excitability: a transcranial magnetic evaluation.
    Goyal V; Bhatia M; Behari M
    Neurol India; 2004 Jun; 52(2):224-7. PubMed ID: 15269477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical and pharmacodynamic correlations of phenobarbital (PB) and diphenylhydantoin (DPH) in the treatment of infantile epilepsy].
    De Negri M; Luciano L
    Minerva Pediatr; 1971 Dec; 23(50):2103-12. PubMed ID: 5135686
    [No Abstract]   [Full Text] [Related]  

  • 11. Interaction of diphenylhydantoin (DPH) and tolbutamide in man.
    Wesseling H; Mols-Thürkow I
    Eur J Clin Pharmacol; 1975; 8(1):75-8. PubMed ID: 1233204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Influencing of the thyroid hormone system by long-term treatment with 5-5 diphenylhydantion in children and adolescens (author's transl)].
    Fichsel H; Knöpfle G
    Klin Padiatr; 1976 Sep; 188(5):435-9. PubMed ID: 987507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of diphenylhydantoin (phenytoin) during pregnancy.
    Landon MJ; Kirkley M
    Br J Obstet Gynaecol; 1979 Feb; 86(2):125-32. PubMed ID: 427051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Change of diphenylhydantoin tolerance at the time of reaching puberty in a 16-year-old girl suffering from epilepsy].
    Wolny H; Rościszewska D; Guz I
    Neurol Neurochir Pol; 1978; 12(5):663-5. PubMed ID: 724040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Plasma levels of diphenylhydantoin (DPH) and phenobarbitone (PB) in epileptic patients resistant to drug treatment (author's transl)].
    Zaccara G; Galli A; Rossi L; Zappoli R; Zatelli L; Amaducci L
    Riv Patol Nerv Ment; 1977; 98(6):363-75. PubMed ID: 754251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of selected parameters of calcium metabolism in epileptics on long-term treatment with diphenylhydantoin].
    Raszeja-Wanic B; Huber Z; Pupek-Musialik D; Saskowski M
    Neurol Neurochir Pol; 1976; 10(4):513-8. PubMed ID: 958581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diphenylhydantoin-induced gingival hyperplasia: its response to changes in drug dosage.
    Little TM; Girgis SS; Masotti RE
    Dev Med Child Neurol; 1975 Aug; 17(4):421-4. PubMed ID: 1158048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One daily dose of diphenylhydantoin (DPH) to patients with epilepsy.
    Strandjord RE; Johannessen SI
    Acta Neurol Scand Suppl; 1972; 51():499-500. PubMed ID: 4514392
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of diphenylhydantoin therapy on folate metabolism of mentally retarded epileptics.
    Arakawa T; Yoshida T; Honda Y; Narisawa K; Hirono H
    Tohoku J Exp Med; 1973 May; 110(1):59-68. PubMed ID: 4729235
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness of simplified dosage schedules on the management of ambulant epileptic patients.
    Zaccara G; Galli A
    Eur Neurol; 1979; 18(5):341-4. PubMed ID: 527610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.